Cytokines and Symptoms in Lung Cancer treatment
肺癌治疗中的细胞因子和症状
基本信息
- 批准号:6924905
- 负责人:
- 金额:$ 16.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-18 至 2007-03-31
- 项目状态:已结题
- 来源:
- 关键词:clinical researchcolorectal neoplasmscombination cancer therapydisease /disorder proneness /riskesophagus neoplasmfatiguehuman subjectinterleukin 1interleukin 10interleukin 12interleukin 6interleukin 8longitudinal human studylung neoplasmsmethod developmentneoplasm /cancer chemotherapyneoplasm /cancer radiation therapysign /symptomtelemedicinetumor necrosis factor alpha
项目摘要
DESCRIPTION (provided by applicant): Patients with lung cancer, colorectal cancer and esophageal cancer experience multiple severe symptoms related to aggressive cancer treatment. Typically these symptoms occur together. Some of the most prevalent of these symptoms, especially cancer-related fatigue, are very difficult to treat and are a major source of distress for patients as well as families. Development of new methods for treating or preventing these symptoms, especially treatments with minimal side effects, is a high priority, but depends on a better understanding of the mechanisms responsible for symptom expression. Previous human and animal studies suggest that high serum levels of cytokines might be one mechanism underlying multiple symptoms (Cleeland, et al, 2003). Interleukin (IL)-6, for example, is known to be elevated in lung and colorectal cancer and to decrease in response to treatment. We propose a study to longitudinally assess the symptoms and the serum levels of a panel of cytokines (IL-1RA, IL-6, IL-8, EL-10, LL-12, and TNF-alpha) in patients with stage TTR or ETI lung, colorectal and esophageal cancer who are undergoing chemoradiation therapy, to (1) characterize the relationship between IL-6 and symptoms over the time of treatment and (2) identify related cytokine(s) (focusing on IL-6) as indicators of high risk for severe fatigue and other symptoms that develop during therapy.
This study will use a novel server-based (interactive voice response) assessment of symptoms on a weekly basis using the M.D. Anderson Symptom Inventory, hi three or four minutes, patients can use their home phones or phones in hospital rooms to rate their symptoms and symptom-related interference. Cytokine sample will be collected before therapy, weekly clinic visit during therapy and at one-month post therapy. Longitudinal methods, such as mixed effect modeling, will be used to assess the strength and nature of the relationship between cytokines and symptoms. These pilot studies may lead to additional multi-disciplinary animal and clinical studies of the mechanisms underlying disease-related and treatment-related cancer symptoms.
描述(由申请人提供):肺癌、结直肠癌和食管癌患者经历与积极癌症治疗相关的多种严重症状。这些症状通常同时出现。其中一些最常见的症状,特别是与癌症有关的疲劳,非常难以治疗,是患者和家庭痛苦的主要来源。开发治疗或预防这些症状的新方法,特别是副作用最小的治疗方法,是一个高度优先事项,但取决于对症状表达机制的更好理解。先前的人类和动物研究表明,细胞因子的高血清水平可能是多种症状的一种潜在机制(Cleeland等人,2003)。例如,已知白细胞介素(IL)-6在肺癌和结肠直肠癌中升高,并且响应于治疗而降低。我们提出了一项研究,纵向评估症状和血清水平的一组细胞因子(IL-1RA、IL-6、IL-8、EL-10、LL-12和TNF-α),(1)表征IL-6与治疗期间症状之间的关系,以及(2)鉴定相关细胞因子(重点是IL-6)作为治疗期间出现的严重疲劳和其他症状的高风险指标。
本研究将使用一种新的基于服务器(交互式语音应答)的症状评估,每周使用医学博士安德森症状量表,在三到四分钟内,患者可以使用家庭电话或病房里的电话来评估他们的症状和与症状相关的干扰。将在治疗前、治疗期间每周门诊访视和治疗后1个月采集细胞因子样本。纵向方法,如混合效应模型,将用于评估细胞因子和症状之间关系的强度和性质。这些初步研究可能会导致额外的多学科动物和临床研究的机制,疾病相关和治疗相关的癌症症状。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xin Shelley Wang其他文献
Patient-reported outcome measures in surgical patients with upper gastrointestinal cancers: A qualitative interview study.
上消化道癌症手术患者患者报告的结果测量:定性访谈研究。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:2.5
- 作者:
Samuel H Cass;L. Williams;Ravi Rajaram;Y. Hirata;David Rice;Ching;Matthew H G Katz;B. Badgwell;Xin Shelley Wang;N. Ikoma - 通讯作者:
N. Ikoma
What Defines the Value of Minimally Invasive Surgery for Cancer Patients?
- DOI:
10.1245/s10434-023-14803-7 - 发表时间:
2023-12-20 - 期刊:
- 影响因子:3.500
- 作者:
Yuki Hirata;Heather Lyu;Grace Li Smith;Xin Shelley Wang;Hop S. Tran Cao;Matthew H. G. Katz;Naruhiko Ikoma - 通讯作者:
Naruhiko Ikoma
Validation and application of a module of the M. D. Anderson symptom inventory for measuring symptom burden in patients with gynecologic cancer (MDASI-PERI-GYN) for perioperative care
- DOI:
10.1016/j.clnesp.2018.03.114 - 发表时间:
2018-06-01 - 期刊:
- 影响因子:
- 作者:
Xin Shelley Wang;Qiuling Shi;Lori Williams;Charles Cleeland;Araceli Garcia;Pedro Tomas Ramirez;Maria Iniesta;Ashley Siverand;Larissa Meyer - 通讯作者:
Larissa Meyer
Investigation of common symptoms of cancer and reliability analysis
- DOI:
10.1007/s11655-007-0195-5 - 发表时间:
2007-09-01 - 期刊:
- 影响因子:2.500
- 作者:
Yi Zhao;Xin Shelley Wang;Ping-ping Li - 通讯作者:
Ping-ping Li
A qualitative study for identifying symptom burden post liver surgery: MDASI-HEP development
- DOI:
10.1016/j.clnesp.2017.04.050 - 发表时间:
2017-06-01 - 期刊:
- 影响因子:
- 作者:
Xin Shelley Wang;Lori Williams;Qiuling Shi;Araceli Garcia Gonzalez;Bradford Kim;Nisha Narula;Catherine Davis;Thomas Aloia - 通讯作者:
Thomas Aloia
Xin Shelley Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xin Shelley Wang', 18)}}的其他基金
Improving Recovery after Major Cancer Surgery using Patient-Reported Outcomes
利用患者报告的结果改善重大癌症手术后的康复
- 批准号:
9310343 - 财政年份:2016
- 资助金额:
$ 16.23万 - 项目类别:
Improving Recovery after Major Cancer Surgery using Patient-Reported Outcomes
利用患者报告的结果改善重大癌症手术后的康复
- 批准号:
9190529 - 财政年份:2016
- 资助金额:
$ 16.23万 - 项目类别:
Effectiveness of minocycline for reducing symptoms in pancreatic cancer patients
米诺环素减轻胰腺癌患者症状的有效性
- 批准号:
8540400 - 财政年份:2012
- 资助金额:
$ 16.23万 - 项目类别:
Effectiveness of minocycline for reducing symptoms in pancreatic cancer patients
米诺环素减轻胰腺癌患者症状的有效性
- 批准号:
8242916 - 财政年份:2012
- 资助金额:
$ 16.23万 - 项目类别:
Inflammatory Cytokines Associated Symptom Burden in NSCLC Patients Receiving CXRT
接受 CXRT 的 NSCLC 患者中炎症细胞因子相关的症状负担
- 批准号:
7532023 - 财政年份:2008
- 资助金额:
$ 16.23万 - 项目类别:
Inflammatory Cytokines Associated Symptom Burden in NSCLC Patients Receiving CXRT
接受 CXRT 的 NSCLC 患者中炎症细胞因子相关的症状负担
- 批准号:
7648219 - 财政年份:2008
- 资助金额:
$ 16.23万 - 项目类别:
Cytokines and Symptoms in Lung Cancer treatment
肺癌治疗中的细胞因子和症状
- 批准号:
7055277 - 财政年份:2005
- 资助金额:
$ 16.23万 - 项目类别:
相似海外基金
Quantitative topographic endoscopy for improved screening of non-polypoid colorectal neoplasms
定量地形内窥镜检查改善非息肉样结直肠肿瘤的筛查
- 批准号:
9769725 - 财政年份:2018
- 资助金额:
$ 16.23万 - 项目类别:
A Comprehensive Approach Encompassing New Therapeutics for Microsatellite-instability Associated Colorectal Neoplasms
包含微卫星不稳定性相关结直肠肿瘤新疗法的综合方法
- 批准号:
25253080 - 财政年份:2013
- 资助金额:
$ 16.23万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
In Vivo Detection of Flat Colorectal Neoplasms with CT Colonography
CT 结肠成像体内检测扁平结直肠肿瘤
- 批准号:
7712639 - 财政年份:2009
- 资助金额:
$ 16.23万 - 项目类别:
MUTANT GENES IN FECES FOR EARLY DETECTION OF COLORECTAL NEOPLASMS
粪便中的突变基因用于早期检测结直肠肿瘤
- 批准号:
6300460 - 财政年份:2000
- 资助金额:
$ 16.23万 - 项目类别:
MUTANT GENES IN FECES FOR EARLY DETECTION OF COLORECTAL NEOPLASMS
粪便中的突变基因用于早期检测结直肠肿瘤
- 批准号:
6102961 - 财政年份:1999
- 资助金额:
$ 16.23万 - 项目类别:
MUTANT GENES IN FECES FOR EARLY DETECTION OF COLORECTAL NEOPLASMS
粪便中的突变基因用于早期检测结直肠肿瘤
- 批准号:
6269643 - 财政年份:1998
- 资助金额:
$ 16.23万 - 项目类别:
MUTANT GENES IN FECES FOR EARLY DETECTION OF COLORECTAL NEOPLASMS
粪便中的突变基因用于早期检测结直肠肿瘤
- 批准号:
6237455 - 财政年份:1997
- 资助金额:
$ 16.23万 - 项目类别:
ANTIOXIDANTS IN CHEMOPREVENTION OF COLORECTAL NEOPLASMS
抗氧化剂用于结直肠肿瘤的化学预防
- 批准号:
3173401 - 财政年份:1984
- 资助金额:
$ 16.23万 - 项目类别:
ANTIOXIDANTS IN CHEMOPREVENTION OF COLORECTAL NEOPLASMS
抗氧化剂用于结直肠肿瘤的化学预防
- 批准号:
3173402 - 财政年份:1984
- 资助金额:
$ 16.23万 - 项目类别:
DOES STREPTOCOCCUS BOVIS SELECTIVELY COLONIZE COLORECTAL NEOPLASMS
牛链球菌是否选择性定植结直肠肿瘤
- 批准号:
3893348 - 财政年份:
- 资助金额:
$ 16.23万 - 项目类别:














{{item.name}}会员




